Current advances in nano drug delivery system for dengue treatment and prevention

Prajakta Jaywant Thorat, Manoj Ramesh Kumbhare, Vaibhavi Vijay Kshatriya, Shraddha Vikas Jadhav, Rushikesh Gajanan Bhambarge

PDF(743 KB)
PDF(743 KB)
Intelligent Pharmacy ›› 2024, Vol. 2 ›› Issue (5) : 723-728. DOI: 10.1016/j.ipha.2024.01.007
Review article

Current advances in nano drug delivery system for dengue treatment and prevention

Author information +
History +

Abstract

Dengue is a most important mosquito-borne viral illnesses. The disease is caused by dengue viruses that have four serotypes: dengue 1, dengue 2, dengue 3 and dengue 4. Primary infection usually results in milder illness, while more severe disease occurs in cases of repeated infection with different serotypes. Nanoparticles can offer significant advantages over the conventional drug delivery in terms of high stability, high specificity, high drug carrying capacity, ability for controlled release, possibility to use in different route of administration and the capability to deliver both hydrophilic and hydrophobic drug molecules. Due to the high prevalence of dengue viruses, it is required to develop novel treatment strategies and provide the site-specific delivery of drug reservoirs.

Keywords

Dengue / Nanoparticles / Serotypes / Aedes

Cite this article

Download citation ▾
Prajakta Jaywant Thorat, Manoj Ramesh Kumbhare, Vaibhavi Vijay Kshatriya, Shraddha Vikas Jadhav, Rushikesh Gajanan Bhambarge. Current advances in nano drug delivery system for dengue treatment and prevention. Intelligent Pharmacy, 2024, 2(5): 723‒728 https://doi.org/10.1016/j.ipha.2024.01.007

References

[1]
Wang WH, Urbina AN, Chang MR, et al. Dengue hemorrhagic fever – a systemic literature review of current perspectives on pathogenesis, prevention and control. J Microbiol Immunol Infect. 2020;53(6):963–978.
CrossRef Google scholar
[2]
Basso CR, Tozato CC, Crulhas BP, Castro GR. An easy way to detect dengue virus using nanoparticle-antibody conjugates. Virology. 2018;513(October 2017):85–90.
CrossRef Google scholar
[3]
Kok BH, Lim HT, Lim CP, Lai NS, Leow CY, Leow CH. Dengue virus infection – a review of pathogenesis, vaccines, diagnosis and therapy. Virus Res. 2023;324(June 2022):199018.
CrossRef Google scholar
[4]
Guzmán G, Kour G. Dengue diagnosis , advances and challenges. 2004;8. https://doi.org/10.1016/j.ijid.2003.03.003.
[5]
Kalayanarooj S. Clinical manifestations and management of dengue/DHF/DSS. 2011;39(4):83–87.
CrossRef Google scholar
[6]
Islam MT, Quispe C, Herrera-Bravo J, et al. Production, transmission, pathogenesis, and control of dengue virus: a literature-based undivided perspective. BioMed Res Int. 2021:2021.
CrossRef Google scholar
[7]
Khetarpal N, Poddar A, Nemani SK, et al. Dengue-specific subviral nanoparticles: design , creation and characterization. Published online. 2013:1–8.
CrossRef Google scholar
[8]
Joudeh N, Linke D. Nanoparticle classification , physicochemical properties , characterization , and applications: a review for biologists. J Nanobiotechnology. Published online. 2022:1–29.
CrossRef Google scholar
[9]
Zhang X feng, Liu Z guo, Shen W, Gurunathan S. Silver Nanoparticles: Synthesis , Characterization , Properties , Applications , and Therapeutic Approaches. 2016. https://doi.org/10.3390/ijms17091534. Published online.
[10]
Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Publ Gr. 2016;2:1–26.
CrossRef Google scholar
[11]
Zacheo A, Hodek J, Witt D, et al. Multi-sulfonated ligands on gold nanoparticles as virucidal antiviral for Dengue virus. Sci Rep. Published online. 2020:1–9. https://doi.org/10.1038/s41598-020-65892-3.
[12]
Hu Y, Hu Y, Sun L, Wong J, Wang M. Antiviral effects of liposome-encapsulated PolyICLC against Dengue virus in a mouse model. Biochem Biophys Res Commun. 2016;478(2):913–918.
CrossRef Google scholar
[13]
Aguiar GR. Pathologic study of a fatal case of dengue-3 virus infection in rio de Janeiro. Brazil. 2005;9:341–347.
CrossRef Google scholar
[14]
Joshi G, Quadir SS, Yadav KS. Road map to the treatment of neglected tropical diseases: nanocarriers interventions. J Contr Release. 2021;339(July):51–74.
CrossRef Google scholar
[15]
Williams KJ. Silver Nanoparticles Inhibit the Binding and Replication of Dengue Virus. 2015. Published online.
[16]
Zohra T. Nanomedicine as a Potential Novel Therapeutic Approach against the Dengue Virus. 2023. September.
CrossRef Google scholar
[17]
Swaminathan G, Thoryk EA, Cox KS, et al. A tetravalent sub-unit dengue vaccine formulated with ionizable cationic lipid nanoparticle induces significant immune responses in rodents and non-human primates. Nat Publ Gr. 2016;(May):1–17.
CrossRef Google scholar
[18]
Sujitha V, Murugan K, Paulpandi M, Vadivalagan C, Chandramohan B, Alarfaj AA. Green-Synthesized Silver Nanoparticles as a Novel Control Tool against Dengue Virus (DEN-2) and its Primary Vector Aedes aegypti. 2015. https://doi.org/10.1007/s00436-015-4556-2. Published online.
[19]
Murugan K, Paulpandi M, Althbyani DM. Nanoparticles in the fight against mosquitoborne diseases: bioactivity of. 2015;114(12):4349–4361.
CrossRef Google scholar
[20]
Seaweed B. Anti -dengue activity of ZnO nanoparticles of crude. Appl Biochem Biotechnol. Published online. 2023:3747–3763.
CrossRef Google scholar
[21]
Buse J. Properties , engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances. R eview. 2010;5:1237–1260.
CrossRef Google scholar
[22]
Vangelie E, Campos R, Oliveira JL De, et al. Recent developments in nanotechnology for detection and control of Aedes aegypti -borne diseases. February. 2020;8:1–17.
CrossRef Google scholar
[23]
Lembo D, Cavalli R, Cliniche S, Torino O. Review Nanoparticulate delivery systems for antiviral drugs. 2010;70:53–70.
CrossRef Google scholar
[24]
Altammar KA. A Review on Nanoparticles: Characteristics , Synthesis, Applications, and Challenges. 2023:1–20. April.
CrossRef Google scholar
[25]
Truzzi E, Nascimento TL, Iannuccelli V, et al. In vivo biodistribution of respirable solid lipid nanoparticles surface-decorated with a mannose-based surfactant: a promising tool for pulmonary tuberculosis treatment? Nanomaterials. 2020;10(3):1–15.
CrossRef Google scholar
[26]
Lopes C, Cristóvão J, Silvério V, Lino PR, Fonte P. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications. Expet Opin Drug Deliv. 2022;19(10):1381–1395.
CrossRef Google scholar
[27]
Fasili Z, Mehri F, Salimi A, et al. Review article: applying nanoparticles in the treatment of viral infections and toxicological considerations. 2019;5(4):1–20.
[28]
Karuppusamy C, Venkatesan P. Role of nanoparticles in drug delivery system: a comprehensive review. 2017;9(3):318–325.
[29]
Shinde NC, Keskar NJ, Argade PD. Nanoparticles: advances in Drug Delivery Systems INTRODUCTION: the types of nanoparticles applied in the drug delivery system include. 2012;1(1):132–137.
[30]
Khanam S, Sheel S, Biswas P, Karmakar V. Ethosome as a potential transdermal drug delivery system. J Pharm Biol Sci. 2023;10(2):72–78.
CrossRef Google scholar
[31]
Yenuganti VR, Afroz S, Khan RA, Bharadwaj C. Milk exosomes elicit a potent anti -viral activity against dengue virus. J Nanobiotechnology. Published online. 2022:1–15.
CrossRef Google scholar
[32]
Lee J hyun. Application of Hydrogel Nanoparticles for Detection of Dengue Virus. 2017. Published online.
[33]
Kekani LN, Witika BA. Discover Nano Current Advances in Nanodrug Delivery Systems for Malaria Prevention and Treatment. Springer US;2023. https://doi.org/10.1186/s11671-023-03849-x.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.
AI Summary AI Mindmap
PDF(743 KB)

Accesses

Citations

Detail

Sections
Recommended

/